RSV MAT
212171
Phase 3 mab terminated
Quick answer
RSV MAT for Respiratory Syncytial Virus Infections is a Phase 3 program (mab) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Respiratory Syncytial Virus Infections
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated